In regard to the methylation of PON1, hypomethylated CpGs in the promoter of PON1 was predicted to be an underlying risk of bleeding after dual antiplatelet therapy.16 Moreover, recent investigations indicated that PON1 had considerable effect on molecular disorders connected with cancer.17, 18, 19 Some researchers found that measurement of serum PON1 concentration post‐radiotherapy could be an efficient prognostic biomarker and an index of the efficacy of the radiotherapy.20 And in this paper, we devoted to explaining the mechanism of PON1 in KIRP. This evidence concerns the gene PON1 and cancer.